Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSCJC3456 in Advanced Malignant Solid Tumors
NCT06717750Phase 1Recruiting
- Sponsor
- Changshan ConjuChem Biopharmaceutical Research and Development (Hebei) Co., Ltd.
- Start
- Feb 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CSCJC3456 in solid tumor, hepatocellular carcinoma (HCC), colorectal cancer (CRC) and 2 more, sponsored by Changshan ConjuChem Biopharmaceutical Research and Development (Hebei) Co., Ltd. Primary endpoints: Dose Limiting Toxicity, Maximum Tolerated Dose and 2 more. Started Feb 2025; status: recruiting.
02
Drugs
CSCJC3456
03
Conditions
solid tumorhepatocellular carcinoma (HCC)colorectal cancer (CRC)gastric cancer (GC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06717750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06717750.